Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q2 2019 Earnings Conference Call - Final Transcript

Aug 01, 2019 • 05:00 pm ET


Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q2 2019 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Good afternoon, ladies and gentlemen, and welcome to the Ultragenyx Second Quarter 2019 Financial Results and Corporate Update.

[Operator Instructions] I would now like to turn the conference over to your host, Ms. Danielle Keatley, you may begin your conference.

Danielle Keatley

Good afternoon and welcome to the Ultragenyx Pharmaceutical Financial Results and Corporate Update Conference Call for the Second Quarter 2019. We have issued a press release detailing our financial results, which you can find on our website at ultragenyx.com. I'm Danielle Keatley, Senior Director of Investor Relations and Corporate Communications.

With me today are Emil Kakkis, Chief Executive Officer and President; Shalini Sharp, Chief Financial Officer; Vlad Hogenhuis, Chief Operating Officer; and Camille Bedrosian, Chief Medical Officer.

I would like to remind investors that this call will include forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act 1995, including but not limited to the types of statements identified as forward looking in our quarterly report on Form 10-Q that will was filed on May 7, 2019. Our quarterly report and Form 10-Q that will be filed soon and our subsequent periodic reports filed with the SEC, which all will be available on our website in the Investor section.

These forward-looking statements represent our views only as of the date of this call and involve substantial risks and uncertainties, including many that are beyond our control. Please note that actual results could differ materially from those projected in any forward-looking statement. For a further description of the risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements as well as risks relating to our business, see our periodic reports filed with the SEC.

I'll now turn the call over to Emil.

Emil D. Kakkis

Good afternoon everyone, and thank you for joining us. I'll start today by providing some brief introductory remarks and before turning the call over to Vlad, who will discuss the commercial performance in the second quarter of 2019. Next, Shalini will update you on the second quarter financial results. Wlad and Camille will then discuss the latest progress across our clinical programs, and I'll come back and discuss the outlook for the rest of the year.

Our commercial momentum continues to grow in the second quarter of this year with strong launch progress in both Crysvita and Mepsevii in three major territories -- throughout the world. Yesterday, we submitted our new drug application for UX007 or triheptanoin for the treatment of long chain fatty acid oxidation disorders. We have relentlessly focused on advancing UX007 through the clinic and into regulatory review, in order to get this therapy to patients as quickly as possible. For our gene therapy platform, we continue to move our two clinical programs forward this quarter, one for the treatment of ornithine transcarbamylase deficiency and the other for Glycogen Storage Disease Type 1a.

Importantly, we recently solidified our mRNA platform by expanding our collaboration and license agreement with Arcturus. The collaboration now